AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

19.740

-0.710-3.47%

Volume:941.98K

Turnover:18.72M

Market Cap:2.50B

PE:126.61

High:20.530

Open:20.090

Low:19.440

Close:20.450

52wk High:23.760

52wk Low:11.000

Shares:126.64M

Float Shares:108.39M

Volume Ratio:1.48

T/O Rate:0.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.156

EPS(LYR):0.233

ROE:6.17%

ROA:2.58%

PB:7.50

PE(LYR):84.83

Loading ...

Overview Company News Filings

NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus

Simply Wall St.

Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million

THOMSON REUTERS

Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug

MT Newswires Live

Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)

THOMSON REUTERS

ASX Biggest Gainers

MT Newswires Live

Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties

Simply Wall St.

Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says

MT Newswires Live

Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark

Neuren Pharmaceuticals Limited-Record Q2 Daybue Net Sales of Us$125m, Cy26 Royalty Upgraded

THOMSON REUTERS

Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54

MT Newswires Live

NewMarket (NEU) Stock Looks Cheap Despite Its 182% Five Year Run

Simply Wall St.

How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate

Simply Wall St.

Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%

Simply Wall St.

Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?

Simply Wall St.

Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue

Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline

MT Newswires Live

Neuren Pharmaceuticals Says DAYBU Recommended for Approval in European Union

Australia's Neuren Jumps as EU Committee Backs Key Drug Authorisation

Neuren Bull Excited by European Regulator Changing Mind on Daybue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":19.74,"timestamp":1788156720000,"preClose":20.45,"halted":0,"volume":941982,"delay":0,"changeRate":-0.034718826405868014,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.155917,"marketStatus":"Not Yet Opened","change":-0.71,"latestTime":"08-31 16:12:00 AEST","open":20.09,"high":20.53,"low":19.44,"amount":18721142,"amplitude":0.053301,"askPrice":19.99,"askSize":5,"bidPrice":19.4,"bidSize":1288,"shortable":3,"etf":0,"ttmEps":0.155917,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":20.45,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.478149,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":20.45,"auctionPrice":19.74,"auctionVolume":320304,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156606439}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"2.58%","roe":"6.17%","lyrEps":0.2327,"volumeRatio":1.478149,"shares":126639526,"dividePrice":0,"high":20.53,"amplitude":0.053301,"preClose":20.45,"low":19.44,"week52Low":11,"pbRate":"7.50","psRate":"35.96","week52High":23.76,"institutionHeld":0,"latestPrice":19.74,"committee":0.992266,"eps":0.155917,"divideRate":0,"volume":941982,"delay":0,"ttmEps":0.155917,"open":20.09,"prevYearClose":18.61,"prevWeekClose":20.45,"prevMonthClose":18,"prevQuarterClose":17.75,"fiveDayClose":22.45,"twentyDayClose":18.59,"sixtyDayClose":13.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NEU.AU","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-16","defaultRemindTime":1789430400000,"name":"NEUREN PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-07","payableDate":"2026-09-16","currency":"AUD","dateTimestamp":1789394400000,"payDate":"2026-10-07"},{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2026-09-15","recordDate":"2026-09-16","paymentDate":"2026-10-07","value":0.15,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663445130","title":"NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2663445130","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663445130?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:22","pubTimestamp":1788088921,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) is back on investor radars after recent share price moves and a fresh look at its valuation profile. The stock closed at US$914.69, with an estimated intrinsic discount of 32.5%.\nOver the past few months NewMarket’s share price has gained momentum, with a 30 day share price return of 7.6% and a 90 day share price return of 14.7%. The 5 year total shareholder return of 193.4% highlights how strongly long term holders have been rewarded.\nSpot similar momentum stories by scanning...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","DECU","VGFPF","BK7096","DCF","BK7508","PMDE","NEU.AU","RGLO","VOTE","GXDW","NEU","FEBU","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763421","title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763421?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704117,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684667","title":"Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:27","pubTimestamp":1787700422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXQDJSS5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204730","title":"Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:10","pubTimestamp":1787616632,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the European Commission gave marketing authorization for Daybu, or trofinetide, for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older to its exclusive global licensee for trofinetide, Acadia Pharmaceuticals, according to a Tuesday Australian bourse filing.Daybu is now authorized to be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, per the filing.Under the companies' license agreement, for Europe, Neuren is entitled to receive $35 million following first commercial sale, potential sales milestone payments of up to $170 million on achievement of escalating annual net sales thresholds, and tiered royalties from mid-teens to low-20s percentage of net sales.Acadia earlier said that a commercial launch in Germany is expected in the December quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","EPV","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662019942","title":"Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662019942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662019942?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUEC7XGBB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693426","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693426?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:27","pubTimestamp":1786073273,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Friday.Mineral 260 : +10%, AU$0.80Light & Wonder CDI : +7%, AU$126.43Iluka Resources : +7%, AU$7.25Pilbara Minerals : +6%, AU$4.57Telix Pharmaceuticals : +6%, AU$15.89Liontown Resources : +6%, AU$1.14Predictive Discovery : +6%, AU$0.77West African Resources : +5%, AU$3.49James Hardie Industries : +5%, AU$42.78Neuren Pharmaceuticals : +4%, AU$22.52","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","TLX.AU","BK7508","NEU.AU","BK7104","MI6.AU","ILU.AU","LNW.AU","PLS.AU","BK7067","BK7506","BK7078","LTR.AU","BK7096","PDI.AU","WAF.AU","JHX.AU","BK7044","BK7507","BK7504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657861486","title":"Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2657861486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657861486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:42","pubTimestamp":1785994942,"startTime":"0","endTime":"0","summary":"In the second quarter of 2026, Neuren Pharmaceuticals reported record DAYBUE net sales of US$125 million, its highest quarterly result since launch, driven by strong uptake of the new DAYBUE STIX powder formulation in the US and supported by positive regulatory progress in Europe.\nThis sales performance led Neuren to upgrade its full-year 2026 royalty income projections, underscoring how formulation innovation and advancing European approvals are influencing its revenue outlook.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508098","title":"Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508098","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508098?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:52","pubTimestamp":1785981135,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657677594","title":"Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2657677594","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657677594?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:34","pubTimestamp":1785900844,"startTime":"0","endTime":"0","summary":"BUZZ-Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark** Shares ofNeuren PharmaceuticalsNEU.AXrise as much as18.2% to A$22.00, theirhighest level since Oct 31, 2025** Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4N4420AJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","LU2065169927.USD","BK7508","LU2065171402.SGD","LU2065171311.SGD","BK4139","BK7096","LU2065170008.USD","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593159","title":"Neuren Pharmaceuticals Limited-Record Q2 Daybue Net Sales of Us$125m, Cy26 Royalty Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657593159?lang=en_us&edition=fundamental","pubTime":"2026-08-05 07:52","pubTimestamp":1785887537,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUE5WT6FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655122638","title":"Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2655122638","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655122638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:30","pubTimestamp":1785360623,"startTime":"0","endTime":"0","summary":"Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652258631","title":"NewMarket (NEU) Stock Looks Cheap Despite Its 182% Five Year Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2652258631","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652258631?lang=en_us&edition=fundamental","pubTime":"2026-07-19 03:22","pubTimestamp":1784402532,"startTime":"0","endTime":"0","summary":"NewMarket stock has delivered a strong 181.8% total return over the past 5 years, and today’s US$770.23 share price sits at a level where both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples still point to the shares trading below what the underlying cash flows may justify.\n\nA 181.8% return over 5 years suggests NewMarket has already rewarded long term holders, so any perceived discount now matters more for new capital being put to work.\nFuture cash generation may...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-stock-looks-cheap-despite-its-182-five-year-ru","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-stock-looks-cheap-despite-its-182-five-year-ru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK4109","BK4588","BK7508","DCF","NEU","SPHQ","BK7096","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651650194","title":"How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2651650194","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651650194?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:26","pubTimestamp":1784111213,"startTime":"0","endTime":"0","summary":"In June 2026, Mount Sinai’s Seaver Autism Center published research in Autism Research estimating Phelan-McDermid syndrome affects about 1 in 7,300 people, a much higher prevalence than earlier thought, in a study supported by CureSHANK and Neuren Pharmaceuticals. \nThis substantially larger patient population estimate highlights a potentially wider addressable market for ongoing precision medicine trials and future therapies targeting Phelan-McDermid syndrome. \nWe’ll now examine how this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-are-reacting-to-neuren-pharmaceuticals-asxneu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-are-reacting-to-neuren-pharmaceuticals-asxneu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","BK7096","NEU.AU","BK7508","ISBC","BK4109","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649853671","title":"Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649853671","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649853671?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368355,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/growth-investors-industry-analysts-just-upgraded-their-neure","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/growth-investors-industry-analysts-just-upgraded-their-neure","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","ISBC","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648570303","title":"Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648570303","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648570303?lang=en_us&edition=fundamental","pubTime":"2026-07-02 15:45","pubTimestamp":1782978356,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency's CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch.\nSee our latest analysis for Neuren Pharmaceuticals.\nThat CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-wins-chmp-backing-is-the-upsid","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-wins-chmp-backing-is-the-upsid","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","CHMP","BK4087","BK7508","NEU.AU","NEU","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130284797","title":"Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue","url":"https://stock-news.laohu8.com/highlight/detail?id=1130284797","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130284797?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:02","pubTimestamp":1782777748,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300779","title":"Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300779","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300779?lang=en_us&edition=fundamental","pubTime":"2026-06-30 07:08","pubTimestamp":1782774529,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.Final approval now depends on the European Commission's decision, which is expected in the coming months.Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647117344","title":"Neuren Pharmaceuticals Says DAYBU Recommended for Approval in European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2647117344","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647117344?lang=en_us&edition=fundamental","pubTime":"2026-06-29 09:31","pubTimestamp":1782696674,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European UnionJune 29 -Neuren Pharmaceuticals LtdNEU.AX:DAYBU RECOMMENDED FOR APPROVAL IN EUROPEAN UNIONIF MARKETING AUTHORISATION GRANTED AND LAUNCHED, CO ENTITLED US$35 MILLION FOLLOWING FIRST COMMERCIAL SALE IN EUFurther company coverage:NEU.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN42Y0IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534113","title":"Australia's Neuren Jumps as EU Committee Backs Key Drug Authorisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534113","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647534113?lang=en_us&edition=fundamental","pubTime":"2026-06-29 08:42","pubTimestamp":1782693743,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren jumps as EU committee backs key drug authorisation** Shares of Neuren PharmaceuticalsNEU.AXadvance as much as 31.4% to A$16.03, their biggest intraday pct gain in over two and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL6N43101O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647349475","title":"Neuren Bull Excited by European Regulator Changing Mind on Daybue","url":"https://stock-news.laohu8.com/highlight/detail?id=2647349475","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647349475?lang=en_us&edition=fundamental","pubTime":"2026-06-29 07:42","pubTimestamp":1782690120,"startTime":"0","endTime":"0","summary":"2342 GMT - Bell Potter raises its price target on Neuren Pharmaceuticals by 6.8% to A$23.50/share after a key European regulator reverses its initial rejection of the trofinetide treatment for Rett Syndrome. Drug advisory body CHMP has decided, after a re-examination, to adopt a positive recommendation. Analyst Thomas Wakim says it's likely that trofinetide, also known as Daybue, will be approved in Europe in around two months. \"The addition of Daybue European sales adds A$2.00/share to our NPV valuation based on current forecasts,\" Bell Potter says. Neuren ended last week at A$12.20.  Dow Jones NewswiresJune 28, 2026 19:42 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","EPV","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}